---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060219"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T15:51:49.180622+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Crinetics reports Q3 net loss of $57.5M; Phase 3 acromegaly study met all endpoints

## Summary
- Phase 3 PATHFNDR-1: 83% paltusotine vs 4% placebo maintained IGF-1 ≤1xULN (p<0.0001); all secondary endpoints met.
- Phase 3 PATHFNDR-2 enrollment completed (112 participants); topline data expected Q1 2024.
- Initial Phase 2 data for paltusotine in carcinoid syndrome expected December 2023; NDA submission planned for 2024.
- Net loss $57.5M vs $41.9M YoY; R&D expenses $43.8M (up $11.8M); G&A $15.5M (up $3.6M).
- Cash $554.7M as of Sep 30, 2023; $350M public offering completed; cash runway into 2026.

## SEC filing metadata
- accession: 0000950170-23-060219
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017023060219/0000950170-23-060219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017023060219/crnx-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060219
- JSON: https://secwatch.observer/filing/0000950170-23-060219.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060219.txt

## Key facts
- Earnings Releases
  Crinetics Pharmaceuticals, Inc. reported third quarter ended September 30, 2023 results: revenue $0.3 million, net income $57.5 million.
  - Period: third quarter ended September 30, 2023
  - Revenue: $0.3 million
  - Net income: $57.5 million
  - Result: reported results
  source text: $3.2 million. • Net loss for the three months ended September 30, 2023, was $57.5 million, compared to a net loss of $41.9 million for the same period in 2022. • Revenues were $0.3 million for the three months ended September 30, 2023, compared to $0.5 million for the same period in 2022. Revenues in both periods were primarily derived from the paltusotine
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000095017023060219/0000950170-23-060219-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.